Atlas Trials

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

Clinical trial NCT07244926 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07244926
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer
Start date
2025-12-01
Primary completion
2027-06-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.